Rivaroxaban — Medical Description

Rivaroxaban is an oral direct factor Xa inhibitor (DOAC) that reduces blood clot formation by selectively inhibiting factor Xa, an essential component of the coagulation cascade. By reducing thrombin generation and clot development, rivaroxaban is used for the prevention and treatment of several clinically important thromboembolic conditions.

Therapeutic Uses

Depending on the approved strength, formulation, age group, and indication, rivaroxaban may be prescribed for:

• Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation.
• Treatment of deep vein thrombosis (DVT).
• Treatment of pulmonary embolism (PE).
• Reduction of the risk of recurrent DVT or PE following initial treatment.
• Prevention of venous thromboembolism (VTE) following hip or knee replacement surgery.
• Certain rivaroxaban regimens are also approved for prevention of thrombotic cardiovascular events in specific high-risk patient populations.

Oral Disintegrating Tablet

An oral disintegrating tablet (ODT) is designed to disintegrate in the mouth and can be useful for patients who have difficulty swallowing conventional tablets. However, the specific administration instructions, bioequivalence, approved strengths, and indications must be confirmed from the product's local regulatory labeling, because not every rivaroxaban indication or strength is available as an ODT.

Rivaroxaban should be taken exactly as prescribed. For formulations/strengths where food affects absorption, administration with food is important; for example, FDA labeling specifies that 15 mg and 20 mg tablets should be taken with food, whereas 10 mg tablets may be taken with or without food.

Typical Adult Dosing

The dose varies substantially according to the indication and kidney function. Examples from FDA labeling include:

*These are examples of approved regimens and must not be used as individualized dosing instructions. Dosing depends on indication, renal function, age, bleeding risk, concomitant medicines, and the specific product labeling.

Important Contraindications & Precautions

Rivaroxaban is contraindicated in patients with active pathological bleeding or a serious hypersensitivity to rivaroxaban or its components.

Particular caution is required in patients with:

• Previous or active gastrointestinal bleeding or ulceration
• Recent major surgery or invasive procedures
• Significant renal impairment
• Significant hepatic impairment or liver disease associated with coagulopathy
• Conditions associated with increased bleeding risk
• Recent intracranial bleeding or neurosurgery
• Patients undergoing spinal/epidural anesthesia or spinal puncture
• Pregnancy or breastfeeding
• Patients with prosthetic heart valves, for whom rivaroxaban is not recommended in the FDA labeling.

Renal function should be assessed when appropriate because impaired kidney function can increase rivaroxaban exposure and bleeding risk.

Important Drug Interactions

Rivaroxaban is affected by medicines that alter P-glycoprotein (P-gp) and CYP3A4 activity. Strong combined P-gp/CYP3A4 inhibitors or inducers can significantly alter rivaroxaban concentrations and may increase either bleeding or thrombotic risk. Concomitant anticoagulants generally should be avoided unless specifically directed by a healthcare professional.

Other medicines that increase bleeding risk—including antiplatelet agents, NSAIDs, and other anticoagulants—should be reviewed by the prescriber before use.

Common & Serious Adverse Effects

The principal adverse effect of rivaroxaban is bleeding, which can occasionally be serious or life-threatening.

Possible adverse effects include:

• Easy bruising
• Nosebleeds
• Gum bleeding
• Prolonged bleeding from cuts
• Gastrointestinal bleeding
• Anemia
• Nausea or gastrointestinal discomfort
• Dizziness or weakness related to blood loss

Seek urgent medical attention for uncontrolled bleeding, vomiting or coughing blood, black/tarry stools, blood in urine, severe headache, sudden weakness, confusion, or other symptoms suggesting major internal bleeding.

Important Patient Information

Do not stop rivaroxaban suddenly without medical advice. Premature discontinuation can increase the risk of thrombotic events, including stroke in appropriately indicated patients.

Patients should inform their doctor, dentist, pharmacist, and surgeon that they are taking rivaroxaban before undergoing procedures or starting new medicines.

Patient Disclaimer

This information is for educational purposes only and is not a substitute for medical advice, diagnosis, or individualized treatment. Rivaroxaban is a prescription anticoagulant and should be used only under the supervision of a qualified healthcare professional. The correct dose and duration depend on the medical indication, kidney and liver function, age, bleeding risk, and other medicines being taken. Do not start, stop, crush, substitute, or change the dose of rivaroxaban without consulting your doctor or pharmacist. In case of severe or uncontrolled bleeding, seek emergency medical care immediately.

References

• U.S. FDA — XARELTO (rivaroxaban) Prescribing Information
• U.S. FDA — Current Rivaroxaban/DailyMed labeling records
• University of Washington Medicine — Anticoagulation Services: Rivaroxaban
• University of California San Diego Health — Anticoagulation Guidelines
• World Health Organization — Essential Medicines / Rivaroxaban information
• World Health Organization — WHO Pharmaceuticals Newsletter